Response to Comment on "Tumor-initiating cells establish an IL-33-TGF-{beta} niche signaling loop to promote cancer progression"
Kamphuis et al. argue that macrophages accumulated in the proximity of tumor-initiating cells do not express the high-affinity immunoglobulin E receptor FcRIα. Although we cannot exclude the possibility of nonspecific binding of anti-FcRIα antibody (clone MAR-1), we provide evidence that macrophages in squamous cell carcinomas express FcRIα and that IL-33 induces FcRIα expression in bone marrow cell–derived macrophages. (Source: ScienceNOW)
Source: ScienceNOW - April 8, 2021 Category: Science Authors: Taniguchi, S., Elhance, A., Van Duzer, A., Kumar, S., Leitenberger, J., Oshimori, N. Tags: Immunology, Medicine, Diseases t-comment Source Type: news

Actinic Keratosis Diagnosis Ups Cumulative Risk for Skin Cancer
MONDAY, March 29, 2021 -- The annual increase in risk for cutaneous squamous cell carcinoma (cSCC) is higher for patients who have received a diagnosis of one or more actinic keratoses (AKs), according to a study published online March 24 in JAMA... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 29, 2021 Category: Pharmaceuticals Source Type: news

Deactivating cancer cell gene boosts immunotherapy for head and neck cancers
By targeting an enzyme that plays a key role in head and neck cancer cells, researchers from theUCLA School of Dentistry were able to significantly slow the growth and spread of tumors in mice and enhance the effectiveness of an immunotherapy to which these types of cancers often become resistant.Their findings,  published online in the journal Molecular Cell, could help researchers develop more refined approaches to combatting highly invasive head and neck squamous cell cancers, which primarily affect the mouth, nose and throat.Immunotherapy, which is used as a clinical treatment for various cancers, harnesses t...
Source: UCLA Newsroom: Health Sciences - March 23, 2021 Category: Universities & Medical Training Source Type: news

2020 British Guidelines for Cutaneous Squamous Cell Carcinoma 2020 British Guidelines for Cutaneous Squamous Cell Carcinoma
Review a summary of the latest updates regarding clinical management of cutaneous squamous cell carcinoma, as presented in the 2020 guidelines from the British Association of Dermatologists.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 23, 2021 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Pivotal Phase III study shows Roche ’s Tecentriq helped people with early lung cancer live longer without their disease returning
Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower010 study evaluating Tecentriq® (atezolizumab), compared with best supportive care (BSC), met its primary endpoint of disease-free survival (DFS) at the interim analysis. Tecentriq showed a statistically significant im provement in DFS as adjuvant therapy following surgery and chemotherapy in all randomised Stage II-IIIA populations with non-small cell lung cancer (NSCLC). The magnitude of DFS benefit was particularly pronounced in the PD-L1-positive population. Follow-up will continue with planned analyses of DFS ...
Source: Roche Investor Update - March 22, 2021 Category: Pharmaceuticals Source Type: news

Pivotal Phase III study shows Roche ’s Tecentriq helped people with early lung cancer live longer without their disease returning
Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower010 study evaluating Tecentriq® (atezolizumab), compared with best supportive care (BSC), met its primary endpoint of disease-free survival (DFS) at the interim analysis. Tecentriq showed a statistically significant im provement in DFS as adjuvant therapy following surgery and chemotherapy in all randomised Stage II-IIIA populations with non-small cell lung cancer (NSCLC). The magnitude of DFS benefit was particularly pronounced in the PD-L1-positive population. Follow-up will continue with planned analyses of DFS ...
Source: Roche Media News - March 22, 2021 Category: Pharmaceuticals Source Type: news

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profi...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Oncotarget: Genomic and neoantigen evolution in head and neck squamous cell carcinoma
(Impact Journals LLC) In this Oncotarget study, the authors characterized the mutational and neoantigen burden between primary and first recurrence tumors in 23 patients with HNSCC. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 17, 2021 Category: Cancer & Oncology Source Type: news

Merck KGaA, Darmstadt, Germany, Builds on Leadership in Head and Neck Cancer Through Worldwide Licensing Agreement with Debiopharm for Pivotal-Stage Xevinapant
Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with current standard of care A Phase II ... Biopharmaceuticals, Oncology, Licensing Merck KGaA, Debiopharm, xevinapant (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 1, 2021 Category: Pharmaceuticals Source Type: news

How Serious Is A Squamous Cell Carcinoma
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - March 1, 2021 Category: General Medicine Source Type: news

GERD Linked to Squamous Cell Cancers of Larynx, Esophagus
MONDAY, Feb. 22, 2021 -- Gastroesophageal reflux disease (GERD) appears to be associated with an increased risk for squamous cell cancers of the larynx and esophagus, according to a study published online Feb. 22 in Cancer. Shao-Ming Wang, Ph.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 22, 2021 Category: Pharmaceuticals Source Type: news

Expert Offers Tips for Sorting Out Pink Lesions on Dermoscopy Expert Offers Tips for Sorting Out Pink Lesions on Dermoscopy
"How can dermoscopy help us distinguish between Spitz nevus, melanoma, clear cell acanthoma, psoriasis, basal cell carcinoma, and squamous cell carcinoma?"Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 2, 2021 Category: Dermatology Tags: Dermatology News Source Type: news

Gene Test Helps Inform Management of High-Risk SCC Patients Gene Test Helps Inform Management of High-Risk SCC Patients
Emerging data support the clinical validity and use of DecisionDx-SCC as a prognostic 40-gene expression profile test for patients with high-risk squamous cell carcinoma.Medscape Medical News (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - February 1, 2021 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Cemiplimab for advanced cutaneous squamous cell carcinoma: survival gains at acceptable cost
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2021 Category: Drugs & Pharmacology Source Type: news

New Amivantamab Data from CHRYSALIS Study Show Robust Clinical Activity and Durable Responses in Patients with Metastatic or Unresectable Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Mutations
January 28, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 1 CHRYSALIS study, which evaluated amivantamab in patients with metastatic or unresectable non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease progressed on or after platinum-based chemotherapy.1 These data were presented for the first time in an oral presentation at the International Association for the Study of Lung Cancer’s (IASLC) 2020 World Conference on Lung Cancer (WCLC) Singapore. The key findings sho...
Source: Johnson and Johnson - January 29, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Reduced-dose RT with Cisplatin improves outcomes for HPV-associated oropharyngeal carcinoma
(NRG Oncology) A combination of reduced-dose radiotherapy using intensity-modulated radiotherapy (IMRT) combined with concurrent cisplatin met the threshold for disease control and quality of life compared to the standard of care for good-risk patients with HPV-associated oropharyngeal squamous cell carcinoma on the NRG Oncology clinical trial NRG-HN002. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 29, 2021 Category: Cancer & Oncology Source Type: news

Does Squamous Cell Cancer Turn into Melanoma
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - January 26, 2021 Category: General Medicine Source Type: news

Janssen to Highlight Commitment to Lung Cancer Science and Innovation with Eight Data Presentations at the International Association for the Study of Lung Cancer ’s 2020 World Conference on Lung Cancer
January 12, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that eight company-sponsored presentations, including two oral presentations, will be featured at the International Association for the Study of Lung Cancer’s (IASLC) 2020 World Conference on Lung Cancer (WCLC) Singapore taking place virtually January 28-31, 2021. The presentations include updated data from the Phase 1 CHRYSALIS study (NCT02609776) evaluating amivantamab in patients with NSCLC and EGFR exon 20 insertion mutations and two studies that characterize the high unmet need and lack of stand...
Source: Johnson and Johnson - January 13, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Oncotarget: PD-1/PD-L1 expression in anal squamous intraepithelial lesions
(Impact Journals LLC) Dr. Margot Bucau from The H ô pital Bichat-Claude Bernard said, " Anal intraepithelial neoplasia (AIN) is the precursor lesion for anal squamous cell carcinomas (ASCC). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 11, 2021 Category: International Medicine & Public Health Source Type: news

Proteogenomics offers insight to treating head and neck squamous cell carcinoma
(Baylor College of Medicine) A new study identifies three molecular subtypes in head and neck squamous cell carcinoma (HNSCC) that could be used to better determine appropriate treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 7, 2021 Category: International Medicine & Public Health Source Type: news

Researchers aim AI at rising oral cancers with $3.3M grant from National Cancer Institute
(Case Western Reserve University) Researchers at Case Western Reserve University and partners in the United States and India are applying artificial intelligence (AI) to help physicians customize treatments for patients with the most common oral cancer, known as squamous cell carcinomas. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 5, 2021 Category: Cancer & Oncology Source Type: news

Rakuten Medical Enrolls First Patient in the U.S. Clinical Trial for its Lead Product, ASP-1929 in Combination with Anti-PD1 Therapy, for Head and Neck Cancer or Cutaneous Squamous Cell Carcinoma
SAN MATEO, Calif., Dec. 23, 2020 -- (Healthcare Sales & Marketing Network) -- Rakuten Medical, Inc. (Rakuten Medical) today announced that their Phase 1b/2 clinical trial, an Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 ... Biopharmaceuticals, Oncology Rakuten Medical, photoimmunotherapy, Illuminox (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 23, 2020 Category: Pharmaceuticals Source Type: news

Janssen Submits Application to U.S. FDA Seeking Approval of Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
RARITAN, N.J., December 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of amivantamab for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy. The application marks the first-ever regulatory submission for the treatment of patients with NSCLC with EGFR exon 20 insertion mutations.[1] The Company...
Source: Johnson and Johnson - December 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Scientists regenerate skin with stem cells to see how DNA defects in kids cause cancer
(Cincinnati Children's Hospital Medical Center) Physicians and scientists at Cincinnati Children's Hospital Medical Center used new stem cell technology to regenerate and study living patient-specific skin in the lab, giving them a precise close up view of how inherited DNA defects cause skin damage and deadly squamous cell carcinoma in children and young adults with Fanconi anemia (FA). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 23, 2020 Category: Cancer & Oncology Source Type: news

First-ever phase 3 clinical trial opens for patients with advanced anal cancer
(ECOG-ACRIN Cancer Research Group) A new clinical trial for metastatic anal cancer will determine if a drug that uses the immune system to fight cancer will prolong progression-free survival when given with standard chemotherapy. Study EA2176 will enroll 205 patients in the US with inoperable advanced (spread to other parts of the body) squamous cell anal cancer. Eligibility includes newly diagnosed patients who have not yet started treatment and patients whose cancer has returned/worsened following surgery or radiation. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 16, 2020 Category: Cancer & Oncology Source Type: news

Icotinib Plus Radiotherapy Ups Survival in Elderly With Esophageal Cancer Icotinib Plus Radiotherapy Ups Survival in Elderly With Esophageal Cancer
Icotinib with concurrent radiotherapy (RT) boosts survival and may have other benefits compared to RT alone in elderly patients with unresectable esophageal squamous cell carcinoma, according to Chinese researchers.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - October 19, 2020 Category: Radiology Tags: Hematology-Oncology News Source Type: news

Can Squamous Cell Carcinoma Spread to Lymph Nodes?
Title: Can Squamous Cell Carcinoma Spread to Lymph Nodes?Category: Diseases and ConditionsCreated: 10/15/2020 12:00:00 AMLast Editorial Review: 10/15/2020 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - October 15, 2020 Category: Dermatology Source Type: news

Black lives also matter in cancer care
(University of Colorado Anschutz Medical Campus) It is not biology, but access to health care that is causing Black Non-Hispanic patients with squamous cell cancer of the head and neck to have lower survival rates. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 1, 2020 Category: Cancer & Oncology Source Type: news

New vulnerability found in lung squamous cancer may facilitate drug targeting
(UNC Lineberger Comprehensive Cancer Center) New cancer research by scientists at UNC Lineberger Comprehensive Cancer Center, and colleagues, shows the potential for targeting a specific circular RNA, known as CDR1as, to attack lung squamous cell cancer. Lung squamous cell cancers comprise up to 30% of all lung cancers and are responsible for about 70,000 new cases and approximately 40,000 deaths each year in the U.S. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 25, 2020 Category: Cancer & Oncology Source Type: news

New First-Line Standard of Care for Esophageal Cancer? New First-Line Standard of Care for Esophageal Cancer?
Pembrolizumab plus chemotherapy should be a new standard of care for first-line treatment, say researchers. Patients with squamous cell carcinomas and higher levels of PD-L1 benefited most.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 23, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

A Breath Test to Diagnose Head and Neck Cancer A Breath Test to Diagnose Head and Neck Cancer
Breath analysis for non-invasive diagnosis of early-stage head and neck squamous cell carcinoma appears to be practical and accurate.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 22, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

What Are Systemic Disease Causes of Oral Ulcers?
Discussion Oral ulcers are common problems seen by dentists but pediatricians also see them. Usually families have are concerned because they are painful and acute. Ulcers are sometime noticed by the physician and not the family as in the case of herpangina or hand-foot and mouth disease. Chronic or recurrent ulcerations present less commonly and therefore it may be more difficult to determine their etiology. Many of the systemic disease causes of oral ulcers are overall infrequent and/or not common in the pediatric age range. Ulcers can be classified in several ways but acute ulcers are usually painful and last less tha...
Source: PediatricEducation.org - September 21, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Robotic surgery may improve outcomes in mouth and throat cancer
(Cedars-Sinai Medical Center) Robotic surgery for patients with early stage, oropharyngeal squamous cell cancer is associated with improved health outcomes, including better long-term survival, according to a Cedars-Sinai study published Thursday in JAMA Oncology. Oropharyngeal cancer occurs in the back of the throat and includes the base of the tongue and tonsils. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 20, 2020 Category: Cancer & Oncology Source Type: news

Researchers ID new target in drive to improve immunotherapy for cancer
FINDINGSResearchers at the UCLA Jonsson Comprehensive Cancer Center and UCLA School of Dentistry  have identified a potential new combination therapy to treat advanced head and neck squamous cell carcinoma, the most common type of head and neck cancer.A study in mice found that using an anti-PD1 immunotherapy drug in combination with PTC209, an inhibitor that targets the protein BMI1, successfully stopped the growth and spread of the cancer, prevented reoccurrences and eliminated cancer stem cells. This is the first preclinical study to provide evidence that targeting BMI1 proteins enhances immunotherapy and eliminate...
Source: UCLA Newsroom: Health Sciences - July 21, 2020 Category: Universities & Medical Training Source Type: news

Researchers ID new target in drive to improve immunotherapy for cancer
(University of California - Los Angeles Health Sciences) UCLA researchers have identified a potential new combination therapy to treat advanced head and neck squamous cell carcinoma, the most common type of head and neck cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 21, 2020 Category: Cancer & Oncology Source Type: news

Tumor-initiating cells establish an IL-33-TGF-{beta} niche signaling loop to promote cancer progression
Targeting the cross-talk between tumor-initiating cells (TICs) and the niche microenvironment is an attractive avenue for cancer therapy. We show here, using a mouse model of squamous cell carcinoma, that TICs play a crucial role in creating a niche microenvironment that is required for tumor progression and drug resistance. Antioxidant activity in TICs, mediated by the transcription factor NRF2, facilitates the release of a nuclear cytokine, interleukin-33 (IL-33). This cytokine promotes differentiation of macrophages that express the high-affinity immunoglobulin E receptor FcRIα and are in close proximity to TICs. ...
Source: ScienceNOW - July 15, 2020 Category: Science Authors: Taniguchi, S., Elhance, A., Van Duzer, A., Kumar, S., Leitenberger, J. J., Oshimori, N. Tags: Cell Biology, Medicine, Diseases, Online Only r-articles Source Type: news

Oncotarget: Tumor markers for carcinoma identified by imaging mass spectrometry
(Impact Journals LLC) Volume 11, Issue 28 of Oncotarget features 'Lipid and protein tumor markers for head and neck squamous cell carcinoma identified by imaging mass spectrometry' by Schmidt et, al. which reported that the authors used MALDI imaging mass spectrometry and immunohistochemistry to seek tumor-specific expression of proteins and lipids in HNSCC samples. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 14, 2020 Category: International Medicine & Public Health Source Type: news

A 3D biofabricated cutaneous squamous cell carcinoma tissue model
(Impact Journals LLC) The cover for issue 27 of Oncotarget features Figure 4, " (A) Bimodal imaging examples of control and treated tumors (red) before and after the treatment period, " by Browning, et al. and reported that the authors developed a 3-dimensional bioprinted skin model of cutaneous squamous cell carcinoma (cSCC) tumors together with a microscopy assay to test chemotherapeutic effects in tissue. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 7, 2020 Category: Cancer & Oncology Source Type: news

Roche improves speed and accuracy of non-small cell lung cancer diagnosis with launch of automated digital pathology algorithm
Basel, June 26, 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the CE-IVD launch of its automated digital pathology algorithm, the uPath PD-L1 (SP263) image analysis for non-small cell lung cancer (NSCLC). The algorithm provides pathologists with automated assessments of scanned slide images that are objective and reproducible and have the potential to aid diagnosis and, ultimately, targeted treatment options for patients. Validated on the VENTANA PD-L1 (SP263) Assay, the algorithm is ready-to-use and integrated within the Roche uPath enterprise software, a universal digital platform for case management, collabo...
Source: Roche Media News - June 26, 2020 Category: Pharmaceuticals Source Type: news

Roche improves speed and accuracy of non-small cell lung cancer diagnosis with launch of automated digital pathology algorithm
             Basel, June 26, 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the CE-IVD launch of its automated digital pathology algorithm, the uPath PD-L1 (SP263) image analysis for non-small cell lung cancer (NSCLC). The algorithm provides pathologists with automated assessments of scanned slide images that are objective and reproducible and have the potential to aid diagnosis and, ultimately, targeted treatment options for patients. Validated on the VENTANA PD-L1 (SP263) Assay, the algorithm is ready-to-use and integrated within the Roche uPath ...
Source: Roche Investor Update - June 26, 2020 Category: Pharmaceuticals Source Type: news

FDA approves pembrolizumab for cutaneous squamous cell carcinoma
Hematology /Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 24, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Merck ’s Keytruda (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that is Not Curable by Surgery or Radiation
KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, as monotherapy for the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 24, 2020 Category: Drugs & Pharmacology Source Type: news

Oncotarget: Bacteriome and mycobiome and bacteriome-mycobiome interactions
(Impact Journals LLC) Volume 11 Issue 25 of @Oncotarget reported that the authors aimed to characterize the bacteriome, mycobiome, and mycobiome-bacteriome interactions of oral wash in Head and neck squamous cell carcinoma, or HNSCC, patients and to determine if they are distinct from those of the oral wash of matched non-Head and neck squamous cell carcinoma patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 23, 2020 Category: Cancer & Oncology Source Type: news

Aspergillosis in the Presence of Squamous Cell Carcinoma
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - June 21, 2020 Category: Respiratory Medicine Authors: MeganB Source Type: news

FDA approves nivolumab for esophageal squamous cell carcinoma
Hematology / Oncology News (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Opdivo (nivolumab) for the Treatment of Patients with Advanced Esophageal Squamous Cell Carcinoma (ESCC) After Prior Fluoropyrimidine- and Platinum-based Chemotherapy
PRINCETON, N.J.--(BUSINESS WIRE) June 10, 2020 Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with unresectable advanced, recurrent... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 10, 2020 Category: Drugs & Pharmacology Source Type: news

SARS-CoV-2 Detected in Tongue Squamous Cell Carcinoma Surgical Specimen SARS-CoV-2 Detected in Tongue Squamous Cell Carcinoma Surgical Specimen
SARS-CoV-2 was detected in tissue specimens from a surgically resected tongue squamous cell carcinoma of a patient who later developed COVID-19, according to a case report.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - May 26, 2020 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Many Patients with Anal Cancer Experienced Chemoradiation Therapy Interruption and Noncompletion
A recent study published in JAMA Oncology revealed that quality improvement initiatives are necessary to optimize treatment and lessen chemotherapy interruption and noncompletion rates among patients with squamous cell anal carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - May 4, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

Erratum for the Research Article: "Epigenetic activation of AP1 promotes squamous cell carcinoma metastasis" by X. Ding, H. Pan, J. Li, Q. Zhong, X. Chen, S. M. Dry, C.-Y. Wang
(Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - April 20, 2020 Category: Science Tags: STKE Errata Source Type: news

How Mohs surgery is used to fight skin cancer: Mayo Clinic Radio Health Minute
Mohs surgery is used to treat the most common skin cancers, basal cell carcinoma and squamous cell carcinoma, as well as some kinds of melanoma. It's especially useful for skin cancers located in areas where it's important to preserve as much healthy skin as possible, such as around the eyes, ears, nose and mouth.  In [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 8, 2020 Category: Databases & Libraries Source Type: news